New drugs and new combinations under development bring a targeted approach to improving care for chronic lymphocytic leukemia (CLL) and for overcoming drug-resistant chronic myeloid leukemia (CML).
"It's an optimistic time for us," says William Wierda, M. D., Ph.D., associate professor in the department of Leukemia, during a video interview about CLL with Andrew Schorr of Patient Power.
In second video interview with Schorr, Jorge Cortes, M.D., professor in the department of Leukemia, discusses drugs in clinical trials that show promise against resistant CML.
Both interviews occurred at the 51st Annual Meeting of the American Society of Hematology in New Orleans Dec. 5-8.
Other M. D. Anderson interviews on Patient Power can be viewed at www.mdanderson.org/patientpower